Literature DB >> 12429950

NF-kappaB and breast cancer.

Harikrishna Nakshatri1, Robert J Goulet.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2002        PMID： 12429950     DOI： 10.1067/mcn.2002.129977

Source DB:  PubMed          Journal:  Curr Probl Cancer        ISSN： 0147-0272            Impact factor:   3.187


× No keyword cloud information.
  18 in total

Review 1.  HER-2 and NF-kappaB as the targets for therapy-resistant breast cancer.

Authors:  Kazi M Ahmed; Ning Cao; Jian Jian Li
Journal:  Anticancer Res       Date:  2006 Nov-Dec       Impact factor: 2.480

2.  Cytoplasmic ERα and NFκB Promote Cell Survival in Mouse Mammary Cancer Cell Lines.

Authors:  Emily Smart; Luis H Alejo; Jonna Frasor
Journal:  Horm Cancer       Date:  2020-02-01       Impact factor: 3.869

3.  Trastuzumab-Resistant Luminal B Breast Cancer Cells Show Basal-Like Cell Growth Features Through NF-κB-Activation.

Authors:  Hirotaka Kanzaki; Nishit K Mukhopadhya; Xiaojiang Cui; V Krishnan Ramanujan; Ramachandran Murali
Journal:  Monoclon Antib Immunodiagn Immunother       Date:  2016-01-21

4.  Dimethyl Fumarate Inhibits the Nuclear Factor κB Pathway in Breast Cancer Cells by Covalent Modification of p65 Protein.

Authors:  Irida Kastrati; Marton I Siklos; Esther L Calderon-Gierszal; Lamiaa El-Shennawy; Gergana Georgieva; Emily N Thayer; Gregory R J Thatcher; Jonna Frasor
Journal:  J Biol Chem       Date:  2015-12-18       Impact factor: 5.157

Review 5.  Anti-cancer activity of new designer hydrogen sulfide-donating hybrids.

Authors:  Khosrow Kashfi
Journal:  Antioxid Redox Signal       Date:  2013-06-07       Impact factor: 8.401

6.  Prognostic value of single nucleotide polymorphisms of candidate genes associated with inflammation in early stage breast cancer.

Authors:  James L Murray; Patricia Thompson; Suk Young Yoo; Kim-Anh Do; Mala Pande; Renke Zhou; Yanhong Liu; Aysegul A Sahin; Melissa L Bondy; Abenaa M Brewster
Journal:  Breast Cancer Res Treat       Date:  2013-03-26       Impact factor: 4.872

Review 7.  Role of trastuzumab in the management of HER2-positive metastatic breast cancer.

Authors:  Andrea Milani; Filippo Montemurro; Luisa Gioeni; Massimo Aglietta; Giorgio Valabrega
Journal:  Breast Cancer (Dove Med Press)       Date:  2010-11-24

8.  IkappaB kinase alpha kinase activity is required for self-renewal of ErbB2/Her2-transformed mammary tumor-initiating cells.

Authors:  Yixue Cao; Jun-Li Luo; Michael Karin
Journal:  Proc Natl Acad Sci U S A       Date:  2007-09-21       Impact factor: 11.205

9.  DEAD-box helicase DP103 defines metastatic potential of human breast cancers.

Authors:  Eun Myoung Shin; Hui Sin Hay; Moon Hee Lee; Jen Nee Goh; Tuan Zea Tan; Yin Ping Sen; See Wee Lim; Einas M Yousef; Hooi Tin Ong; Aye Aye Thike; Xiangjun Kong; Zhengsheng Wu; Earnest Mendoz; Wei Sun; Manuel Salto-Tellez; Chwee Teck Lim; Peter E Lobie; Yoon Pin Lim; Celestial T Yap; Qi Zeng; Gautam Sethi; Martin B Lee; Patrick Tan; Boon Cher Goh; Lance D Miller; Jean Paul Thiery; Tao Zhu; Louis Gaboury; Puay Hoon Tan; Kam Man Hui; George Wai-Cheong Yip; Shigeki Miyamoto; Alan Prem Kumar; Vinay Tergaonkar
Journal:  J Clin Invest       Date:  2014-08-01       Impact factor: 14.808

10.  BRMS1 suppresses breast cancer metastasis in multiple experimental models of metastasis by reducing solitary cell survival and inhibiting growth initiation.

Authors:  Benjamin D Hedley; Kedar S Vaidya; Pushar Phadke; Lisa MacKenzie; David W Dales; Carl O Postenka; Ian C MacDonald; Ann F Chambers
Journal:  Clin Exp Metastasis       Date:  2008-06-10       Impact factor: 5.150
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.